Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60

Yi Chao Foong, Daniel Merlo, Melissa Gresle, Katherine Buzzard, Michael Zhong, Wei Zhen Yeh, Vilija Jokubaitis, Mastura Monif, Olga Skibina, Serkan Ozakbas, Francesco Patti, Pierre Grammond, Maria Pia Amato, Tomas Kalincik, Dana Horakova, Eva Kubala Havrdova, Bianca Weinstock-Guttman, Jeanette Lechner Scott, Cavit Boz, Maria Jose SaHelmut Butzkueven, Anneke van der Walt, Chao Zhu, on behalf of the MSBase Study Group

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)


Background Ongoing controversy exists regarding optimal management of disease modifying therapy (DMT) in older people with multiple sclerosis (pwMS). There is concern that the lower relapse rate, combined with a higher risk of DMT-related infections and side effects, may alter the risk-benefit balance in older pwMS. Given the lack of pwMS above age 60 in randomised controlled trials, the comparative efficacy of high-efficacy DMTs such as ocrelizumab has not been shown in older pwMS. We aimed to evaluate the comparative effectiveness of ocrelizumab, a high-efficacy DMT, versus interferon/glatiramer acetate (IFN/GA) in pwMS over the age of 60. Methods Using data from MSBase registry, this multicentre cohort study included pwMS above 60 who switched to or started on ocrelizumab or IFN/GA. We analysed relapse and disability outcomes after balancing covariates using an inverse probability treatment weighting (IPTW) method. Propensity scores were obtained based on age, country, disease duration, sex, baseline Expanded Disability Status Scale, prior relapses (all-time, 12 months and 24 months) and prior DMT exposure (overall number and high-efficacy DMTs). After weighting, all covariates were balanced. Primary outcomes were time to first relapse and annualised relapse rate (ARR). Secondary outcomes were 6-month confirmed disability progression (CDP) and confirmed disability improvement (CDI). Results A total of 248 participants received ocrelizumab, while 427 received IFN/GA. The IPTW-weighted ARR for ocrelizumab was 0.01 and 0.08 for IFN/GA. The IPTW-weighted ARR ratio was 0.15 (95% CI 0.06 to 0.33, p<0.001) for ocrelizumab compared with IFN/GA. On IPTW-weighted Cox regression models, HR for time to first relapse was 0.13 (95% CI 0.05 to 0.26, p<0.001). The hazard of first relapse was significantly reduced in ocrelizumab users after 5 months compared with IFN/GA users. However, the two groups did not differ in CDP or CDI over 3.57 years. Conclusion In older pwMS, ocrelizumab effectively reduced relapses compared with IFN/GA. Overall relapse activity was low. This study adds valuable real-world data for informed DMT decision making with older pwMS. Our study also confirms that there is a treatment benefit in older people with MS, given the existence of a clear differential treatment effect between ocrelizumab and IFN/GA in the over 60 age group.

Original languageEnglish
Article number332883
Number of pages8
JournalJournal of Neurology, Neurosurgery and Psychiatry
Publication statusAccepted/In press - 7 Mar 2024

Cite this